SPOTLIGHT -
Review of agents in late-stage development for the treatment of selected dermatologic disorders (December 2005).
Evernorth to Offer Private Label Humira Biosimilar
Beginning in June 2024, Quallent Pharmaceuticals will provide Evernorth a high- and low-concentration interchangeable biosimilar of Humira.
FDA Approves Ojemda for Children with Brain Tumors
Ojemda will have a wholesale acquisition cost of $33,916 for a 28 day supply and will be distributed through specialty pharmacies Biologics by McKesson and Onco360.
No Silver Bullet for Paying for Gene Therapies
New White Paper looks at the solutions and policy options of how to pay for high-cost gene therapies when there is still so much uncertainty about the outcomes and the durability of clinical benefits.
Discoloration Leads to Recall of Sapropterin Products
Dr. Reddy’s is recalling five lots of Javygtor and one lot of generic sapropterin dihydrochloride because discoloration could lead to decreased potency. Sapropterin is used to treat an inherited metabolic disorder.
FDA Approves Lutathera for Adolescents with Neuroendocrine Tumors
Lutathera is a radiotherapeutic that is now approved for patients 12 years and older neuroendocrine tumors in the pancreas or gastrointestinal tract.
FDA Approves Bladder Cancer Immunotherapy
ImmunityBio’s Anktiva is an antibody cytokine fusion protein approved to treat patients with non-muscle invasive bladder cancer.